Extraneural Glioblastoma Metastasis: A Case Report

*Selcuk Demiral, Omer Sager, Ferrat Dincoglan, Bora Uysal, Hakan Gamsiz, Yelda Elcim, Bahar Dirican and Murat Beyzadeoglu

Department of Radiation Oncology, University of Health Sciences, Turkey

Submission: October 03, 2017; Published: October 23, 2017

Correspondence Address: Selcuk Demiral, Associate Professor, Department of Radiation Oncology, Gulhane Medical Faculty, University of Health Sciences, gn.tevfik saglam cad. 06018, etlik, kecioren Ankara, Turkey, Tel: +90 312 304 4689; Fax: +90 312 304 4680; Email: drs.demiral@hotmail.com

Abstract

Glioblastomas comprise the most common and the most malignant of primary brain tumors with a dismal prognosis. While local failure is very common even after definitive multimodality management, extracranial distant metastasis is extremely infrequent due to the absence of lymphatic drainage. In this case report, we present a 44-year-old male patient presenting with an intracranial lesion who was diagnosed to have World Health Organization (WHO) grade II oligodendroglioma following subtotal excision. Conventionally fractionated radiotherapy at a dose of 54 Gy was delivered to the local cranium after surgery. After 3 years of follow-up without progression, he was diagnosed with recurrent disease and the histopathological assessment revealed a WHO grade IV glioblastoma with malignant transformation. He had bone metastasis together with an involved neck node by direct extension. Symptomatic relief was achieved after salvage chemoradiation. The patient is still alive after 4 years from the first diagnosis. Extracranial neck node metastasis together with bone metastasis of glioblastoma may be seen though very rarely reported in the literature. Substantial improvement in symptoms may be achieved with multimodality management in the setting of the very rare occurrence of extraneural glioblastoma metastasis.

Keywords: Glioblastoma; Metastasis; Extraneural; Radiotherapy

Abbreviations: WHO: World Health Organization; Gy: Gray

Introduction

Malignant gliomas including World Health Organization (WHO) grade IV glioblastoma and WHO grade III anaplastic astrocytoma, mixed anaplastic oligoastrocytoma, and anaplastic oligodendroglioma have an incidence of approximately 5/100000 [1]. Glioblastomas may be classified as primary and secondary glioblastomas. Glioblastoma is the most aggressive form of primary brain tumors which usually occurs “de novo” or by the malignant transformation of low-grade tumors in several years [2].

Figure 1: Intracranial lesion, metastatic cervical lymph nodes, and bone metastasis of the glioblastoma patient shown on MRI.
Case Report

A 44-year old male patient with complaints of headache and right-sided paresis was referred to the Neurosurgery department. Brain MRI revealed a left parieto-temporal mass and he underwent a subtotal resection. Histopathological assessment revealed a WHO Grade II Oligodendrogloma. He was referred to the Radiation Oncology Department and partial brain irradiation of 54 Gy was delivered. He was followed up periodically after radiotherapy. After 3 years of follow-up without progression, he had complaints of a left-sided neck mass. Neck ultrasound revealed a cystic lymphadenopathy of 28x18 mm on left cervical neck region. Brain MRI then revealed 7x7x9 cm cystic residual mass in the left temporal lobe, left centrum semiovale, left basal ganglia which infiltrated the left nasopharyngeal wall with a large edema. Figure 1 shows the intracranial lesion, metastatic cervical lymph nodes, and cervicothoracic bone metastasis of the glioblastoma patient.

Neck MRI revealed multiple left cervical adenopathies and metastasis at the cervicothoracic vertebrae. Bone scan confirmed the bone metastasis including sacrilacs. The neck adenopathy excision was performed and a histopathological diagnosis of glioblastoma with metastatic oligodendrogial component was revealed on histopathologic assessment. The additional radiation dose to be delivered to the lesion after 3 years from the initial radiotherapy course of 54 Gy was calculated, and he was delivered 20 Gy partial brain reirradiation, 60 Gy neck irradiation, and 30 Gy bilateral sacralcic bone irradiation concurrent with 75mg/m2 temozolomide was followed by adjuvant temozolomide 200mg/m2 at the first 5 consecutive days of every 28-day cycles. Symptomatic relief was achieved after salvage chemoirradiation. The patient is still alive after 4 years of the first diagnosis.

Discussion

Extracranial metastasis of glioblastoma is an extremely rare event, particularly in elderly patients [3,4]. Pasquier et al. reported metastasis rates of 51% in the regional lymph nodes, 60% in lung and the pleura, 31% in bones, and 22% in the liver [5]. Even simultaneous leptomeningeal and intramedullary metastases have been described in the literature [6]. Metastasis of glioblastoma is uncommon due to the lack of cerebral lymphatic system flows towards internal jugular vein [8]. Hematogenous metastases may be seen at bones, mostly in the vertebrae [3]. Lymph node metastasis occurs through the relations between perineural area and the lymphatic plexuses [5]. In our case, brain and neck MRI and CT revealed left neck lymphadenopathy, direct invasion to left nasopharyngeal wall, and involvement of cervicothoracic vertebrae. Extracranial metastasis was confirmed by lymph node biopsy which revealed metastasis of glioblastoma. In conclusion, extracranial neck node metastasis and bone metastasis of glioblastoma may be seen though very rarely reported in the literature. Substantial improvement in symptoms may be achieved with multimodality management in the setting of rarely seen extraneural glioblastoma metastasis.

Conflict of Interest

There is no conflict of interest.

References
